Skip to Content

Posts tagged with "The Central Nervous System"

  • Press Coverage

    CMPI Conference: CATIE and ALLHAT

    The third conference is on the CATIE and ALLHAT trials, the large comparative studies of antipsychotic and hypertensive medications. These studies are taking a real beating, I have to say. Herbert Meltzer of Vanderbilt took on the CATIE work, saying that its design was too complex and tried to do too many things at once. Read More
  • Cardiovascular Disease

    It Should Work. It Just Doesn’t.

    The late-stage clinical failure of a small company/big company drug partnership story gets told over and over, and today it was the turn of Renovis and AstraZeneca. Renovis had come up with a candidate (NXY-059) for post-stroke therapy that targeted free-radical oxidative damage. Initial clinical trials were fairly positive, but this latest one, a… Read More
  • The Central Nervous System

    Touch Me Not

    I see that Dylan found an old bottle of L-DOPA in his stockroom – I’d handle that one with gloves, but that’s the medicinal chemist in me talking. He segues into a discussion of the MPTP story, which I talked about here a while back. Every med-chemist who’s done work on central nervous system drugs… Read More
  • Business and Markets

    Neurocrine’s Choice

    It’s been an awful time to hold the stock of a small company called Neurocrine. They’ve been developing an insomnia therapy (Indiplon), and things seemed to be going along reasonably well. It’s a crowded field. The compound is in the same GABA mechanistic class as the existing drug Ambien (which makes it in the same… Read More
  • The Central Nervous System

    Tied to the Mast

    Some readers will have already come across reports suggesting that some drugs for Parkinson’s disease can lead to odd behavioral problems, including compulsive gambling. Given their effects on dopaminergic pathways, which seem to be involved in stimulus/reward behavior, it’s a believable effect. (Actually, as I mentioned the other day,… Read More
  • "Me Too" Drugs

    By a Nose in a Head to Head

    One of the other incorrect lessons that people might take away from the press accounts of the antipsychotic trial is that drug companies have been comparing their medications to placebo too often. And why would you do that unless you were scared that you wouldn’t be better than the competition? What’s with these people, anyway?… Read More
  • "Me Too" Drugs

    No Clear Winners

    You’ve probably seen the headlines about the recent NIH-sponsored “CATIE” study comparing five anti-psychotic medications. The result, which is what made the whole thing newsworthy to the popular press, was that it was hard to distinguish among them, with the oldest generic working as well as (or better than) the newer drugs. But… Read More
  • Drug Industry History

    The Painful History of Substance P

    I had a question from a reader about Substance P, a peptide that’s been known since the 1930s as something that was involved in pain and neurotransmission. Its biological target is the neurokinin receptor subtype NK1, and there’s been a huge amount of research on this system over the years, studying its role in the… Read More
  • Drug Development

    Morphine in the Brain: Go For It, or Not?

    So, I do a post where I wonder if the reductionist target-driven approach to drug discovery is running out of gas, then I do one on the possibility of some interesting new drug targets in the brain. Am I deliberately talking out of both sides of my mouth, or do I just not remember what… Read More
  • The Central Nervous System

    More Brain Surprises

    All sorts of odd things have turned out to be neurotransmitters, that’s for sure. I wrote about this over a year ago, in a post about hydrogen sulfide, of all things, and its role in the brain. Well, there’s another odd one that’s been uncovered. And like hydrogen sulfide (or carbon monoxide, also a neurotransmitter… Read More